RxSight Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
RXST$4.90+0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating Activities: | ||
| Net loss | $(21,517) | $(39,431) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 3,060 | 3,027 |
| Provision for bad debts | 34 | — |
| Amortization of right-of-use lease assets | 41 | 132 |
| Amortization of debt issuance costs and premium | — | 287 |
| Loss on extinguishment of debt | — | 1,769 |
| Amortization of discount on short-term investments | (6,349) | (4,545) |
| Stock-based compensation | 17,353 | 11,321 |
| Provision for excess and obsolete inventory | 333 | 13 |
| Change in operating assets and liabilities: | ||
| Accounts receivable | (5,121) | (4,288) |
| Inventories | (4,585) | (4,101) |
| Prepaid and other assets | 850 | 997 |
| Accounts payable | 830 | 1,408 |
| Accrued expenses and other liabilities | 2,385 | 119 |
| Net cash used in operating activities | (12,686) | (33,292) |
| Investing Activities: | ||
| Purchase of property and equipment | (4,593) | (3,223) |
| Maturity of short-term investments | 188,000 | 205,000 |
| Purchases of short-term investments | (284,038) | (228,472) |
| Net cash used in investing activities | (100,631) | (26,695) |
| Financing Activities: | ||
| Proceeds from term loan | — | 20,000 |
| Repayment of term loan | — | (60,000) |
| Proceeds from issuance of common stock from public offering | 108,100 | 54,050 |
| Proceeds from issuance of common stock from at-the-market offerings | — | 42,433 |
| Proceeds from issuance of common stock | 17,828 | 5,890 |
| Payments for employee taxes related to stock compensation | (4,768) | (1,421) |
| Principal payments on finance lease liabilities | (49) | (119) |
| Payments of deferred offering costs | (768) | (647) |
| Payments of debt issuance costs | — | (2,224) |
| Net cash provided by financing activities | 120,343 | 57,962 |
| Effect of foreign exchange rate on cash, cash equivalents and restricted cash | 3 | (2) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 7,029 | (2,026) |
| Cash, cash equivalents and restricted cash - beginning of period | 10,402 | 12,595 |
| Cash, cash equivalents and restricted cash - end of period | $17,431 | $10,569 |
| Supplemental disclosure of cash flow information: | ||
| Operating cash flows from operating leases | 1,633 | 1,666 |
| Cash paid for income taxes | 26 | 12 |
| Cash paid for interest on financing leases | 16 | 8 |
| Cash paid for interest on term loan | — | 3,464 |
| Non-cash investing and financing activities: | ||
| Right-of-use assets obtained in exchange for lease obligations: | ||
| Operating lease | 9,060 | 8 |
| Finance lease | 19 | — |
| Lease obligations recorded for right-of-use assets: | ||
| Operating lease | 9,060 | 8 |
| Finance lease | 19 | — |
| Acquisition of property and equipment included in accounts payable and accrued expenses and other current liabilities | 393 | 211 |
| Deferred offering and financing costs included in accounts payable and accrued liabilities | — | 159 |
| Reclassification of deferred financing costs | 768 | 1,300 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.